Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRS01 in active non-infectious anterior uveitis
NCT04222712Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2020
- Primary completion
- Aug 2020
- Countries
- 1
- Sponsor
- Tarsier Pharma
- Modality
- Peptides, Small Molecules
- Drugs
- dazdotuftide
01
Overview
Phase 2, randomised, double-blind trial of dazdotuftide (2 arms), sponsored by Tarsier Pharma. Primary endpoint: Assessment of Both Systemic and Ocular Adverse Events at 10 weeks. Started Feb 2020; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
TRS01 low dose
TRS01 eye drops administered QID
TRS01 high dose
TRS01 eye drops administered QID
03
Who it enrols
Adults with active non-infectious anterior uveitis (AC cells Grade 2 or 3) requiring steroid initiation/increase, with vision ≥ 20/40 in the non-study eye.
04
Endpoints
Primary
Assessment of Both Systemic and Ocular Adverse Events
Beyond the preview
Go deeper on NCT04222712.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04222712.